collection
https://read.qxmd.com/read/25871574/a-critical-interaction-between-ertapenem-and-valproic-acid
#21
LETTER
Gabor P Molnar, Kyle J Stephens, Lauren V George, Jonathan T Stewart
No abstract text is available yet for this article.
June 2015: Journal of Clinical Psychopharmacology
https://read.qxmd.com/read/25874915/insomnia-and-somnolence-associated-with-second-generation-antidepressants-during-the-treatment-of-major-depression-a-meta-analysis
#22
JOURNAL ARTICLE
Siegfried Alberti, Alberto Chiesa, Costanza Andrisano, Alessandro Serretti
BACKGROUND: Sleep reduction or enhancement is frequently observed with second-generation antidepressant treatments, and they can be beneficial or harmful depending on the symptom profile of each subject. Nevertheless, relatively little attention has been given so far to rank those effects across compounds. The aim of this meta-analysis is to provide quantitative data about short-term rates of insomnia and somnolence associated with 14 second-generation antidepressants during the treatment of major depression...
June 2015: Journal of Clinical Psychopharmacology
https://read.qxmd.com/read/25882763/a-13-week-randomized-double-blind-placebo-controlled-cross-over-trial-of-ziprasidone-in-bipolar-spectrum-disorder
#23
RANDOMIZED CONTROLLED TRIAL
Ashwin A Patkar, Chi-Un Pae, Paul A Vöhringer, Sivan Mauer, Meera Narasimhan, Shannon Dalley, Antony Loebel, Prakash S Masand, S Nassir Ghaemi
OBJECTIVE: Features of bipolarity in a major depressive disorder sample were used to define a "bipolar spectrum disorder" population for treatment with a neuroleptic agent, ziprasidone. METHODS: Forty-nine acutely depressed patients were randomized to ziprasidone-washout-placebo or placebo-washout-ziprasidone in this double-blind, prospective, 13-week crossover trial. All patients met the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, criteria for a major depressive episode and were positive for at least 3 predictors of bipolarity: family history of bipolar disorder, antidepressant-induced mania, highly recurrent depressive episodes (>5), atypical depression, early onset of depression (<age 20), failure to respond to antidepressants or antidepressant tolerance...
June 2015: Journal of Clinical Psychopharmacology
https://read.qxmd.com/read/25928702/exacerbation-of-tics-after-combining-aripiprazole-with-pimozide-a-case-with-tourette-syndrome
#24
LETTER
Betül Mazlum, Sennur Zaimoğlu, Didem Behice Öztop
No abstract text is available yet for this article.
June 2015: Journal of Clinical Psychopharmacology
https://read.qxmd.com/read/25928701/concomitant-benzodiazepine-use-attenuates-ketamine-response-implications-for-large-scale-study-design-and-clinical-development
#25
LETTER
Mark A Frye, Pierre Blier, Susannah J Tye
No abstract text is available yet for this article.
June 2015: Journal of Clinical Psychopharmacology
https://read.qxmd.com/read/24974829/correlates-of-attitudes-towards-mood-stabilizers-in-individuals-with-bipolar-disorder
#26
JOURNAL ARTICLE
Ching-Wen Chang, Martha Sajatovic, Curtis Tatsuoka
OBJECTIVES: Attitudes towards medication are believed to be important for medication adherence and social factors are believed to have effects on attitudes. Only a limited literature has focused on how attitudes to medication may correlate with social factors relevant to medication adherence among individuals with bipolar disorder (BPD). This secondary analysis of baseline data from a longitudinal study examined the relationships between attitudes towards mood stabilizers and psychosocial variables...
February 2015: Bipolar Disorders
https://read.qxmd.com/read/25070221/risk-factors-for-polyuria-in-a-cross-section-of-community-psychiatric-lithium-treated-patients
#27
JOURNAL ARTICLE
James Conor Kinahan, Aoife NiChorcorain, Sean Cunningham, Aideen Freyne, Colm Cooney, Siobhan Barry, Brendan D Kelly
OBJECTIVES: Polyuria increases the risk of dehydration and lithium toxicity in lithium-treated patients. Risk factors have been inconsistently described and the variance of this adverse effect remains poorly understood. This study aimed to establish independent risk factors for polyuria in a community, secondary-level lithium-treated sample of patients. METHODS: This was a cross-sectional study of the lithium-treated patients attending a general adult and an old age psychiatry service...
February 2015: Bipolar Disorders
https://read.qxmd.com/read/25056368/the-efficacy-and-tolerability-of-cariprazine-in-acute-mania-associated-with-bipolar-i-disorder-a-phase-ii-trial
#28
RANDOMIZED CONTROLLED TRIAL
Suresh Durgam, Anju Starace, Dayong Li, Raffaele Migliore, Adam Ruth, György Németh, István Laszlovszky
OBJECTIVES: Cariprazine, an orally active and potent dopamine D3 and D2 receptor partial agonist with preferential binding to D3 receptors, is being developed for the treatment of schizophrenia and bipolar mania. This Phase II trial evaluated the efficacy, safety, and tolerability of cariprazine versus placebo in the treatment of acute manic or mixed episodes associated with bipolar I disorder. METHODS: This was a multinational, randomized, double-blind, placebo-controlled, flexible-dose study of cariprazine 3-12 mg/day in patients with acute manic or mixed episodes associated with bipolar I disorder...
February 2015: Bipolar Disorders
https://read.qxmd.com/read/25257942/longer-lithium-exposure-is-associated-with-better-white-matter-integrity-in-older-adults-with-bipolar-disorder
#29
JOURNAL ARTICLE
Ariel G Gildengers, Meryl A Butters, Howard J Aizenstein, Megan M Marron, James Emanuel, Stewart J Anderson, Lisa A Weissfeld, James T Becker, Oscar L Lopez, Benoit H Mulsant, Charles F Reynolds
OBJECTIVES: Bipolar disorder (BD) is associated with cognitive dysfunction and structural brain abnormalities. In human and non-human studies, lithium has been related to neuroprotective and neurotrophic effects. We explored whether lithium treatment is related to better brain integrity and cognitive function in older adults with BD. METHODS: We examined cognitive and neuroimaging data in 58 individuals with BD [mean (standard deviation) age = 64.5 (9.8) years] and 21 mentally healthy comparators (controls) of similar age and education...
May 2015: Bipolar Disorders
https://read.qxmd.com/read/25295837/clozapine-use-reduced-psychiatric-hospitalization-and-emergency-room-visits-in-patients-with-bipolar-disorder-independent-of-improved-treatment-regularity-in-a-three-year-follow-up-period
#30
JOURNAL ARTICLE
Chi-Shin Wu, Sheng-Chang Wang, Shi-Kai Liu
OBJECTIVES: The efficacy of clozapine in bipolar disorder remains to be systemically examined. In the current study, we sought to disentangle the effect of clozapine from that of improved treatment regularity and to compare the effect of clozapine with the effect of regular treatment for bipolar disorder by exploring the complete 10-year clozapine prescription data from a Taiwanese total population health claims database. METHODS: In the period between 2000 and 2009, 3,874 (3...
June 2015: Bipolar Disorders
https://read.qxmd.com/read/25346322/clozapine-for-treatment-resistant-bipolar-disorder-a-systematic-review
#31
REVIEW
Xian-Bin Li, Yi-Lang Tang, Chuan-Yue Wang, Jose de Leon
OBJECTIVE: To evaluate the efficacy and safety of clozapine for treatment-resistant bipolar disorder (TRBD). METHODS: A systematic review of randomized controlled studies, open-label prospective studies, and retrospective studies of patients with TRBD was carried out. Interventions included clozapine monotherapy or clozapine combined with other medications. Outcome measures were efficacy and adverse drug reactions (ADRs). RESULTS: Fifteen clinical trials with a total sample of 1,044 patients met the inclusion criteria...
May 2015: Bipolar Disorders
https://read.qxmd.com/read/25400146/a-single-infusion-of-ketamine-improves-depression-scores-in-patients-with-anxious-bipolar-depression
#32
RANDOMIZED CONTROLLED TRIAL
Dawn F Ionescu, David A Luckenbaugh, Mark J Niciu, Erica M Richards, Carlos A Zarate
OBJECTIVE: Patents with anxious bipolar disorder have worse clinical outcomes and are harder to treat with traditional medication regimens compared to those with non-anxious bipolar disorder. Ketamine has been shown to rapidly and robustly decrease symptoms of depression in depressed patients with bipolar disorder. We sought to determine whether baseline anxiety status reduced ketamine's ability to decrease symptoms of depression. METHODS: Thirty-six patients with anxious (n = 21) and non-anxious (n = 15) treatment-resistant bipolar depression (types I and II; concurrently treated with either lithium or valproate) received a single infusion of ketamine (0...
June 2015: Bipolar Disorders
https://read.qxmd.com/read/21320390/evidence-based-pharmacotherapy-for-personality-disorders
#33
REVIEW
Luis H Ripoll, Joseph Triebwasser, Larry J Siever
Patients with personality disorders are prescribed psychotropic medications with greater frequency than almost any other diagnostic group. Prescribing practices in these populations are often based on anecdotal evidence rather than rigorous data. Although evidence-based psychotherapy remains an integral part of treatment, Axis II psychopathology is increasingly conceptualized according to neurobiological substrates that correspond to specific psychopharmacological strategies. We summarize the best available evidence regarding medication treatment of personality disordered patients and provide optimal strategies for evidence-based practice...
October 2011: International Journal of Neuropsychopharmacology
https://read.qxmd.com/read/25706219/treatment-of-personality-disorder
#34
JOURNAL ARTICLE
Anthony W Bateman, John Gunderson, Roger Mulder
The evidence base for the effective treatment of personality disorders is insufficient. Most of the existing evidence on personality disorder is for the treatment of borderline personality disorder, but even this is limited by the small sample sizes and short follow-up in clinical trials, the wide range of core outcome measures used by studies, and poor control of coexisting psychopathology. Psychological or psychosocial intervention is recommended as the primary treatment for borderline personality disorder and pharmacotherapy is only advised as an adjunctive treatment...
February 21, 2015: Lancet
https://read.qxmd.com/read/24911438/discontinuation-of-antidepressants-during-attempts-to-conceive-a-pilot-trial-of-cognitive-behavioral-therapy-for-the-prevention-of-recurrent-depression
#35
JOURNAL ARTICLE
Christina Psaros, Marlene Freeman, Steven A Safren, Maria Barsky, Lee S Cohen
BACKGROUND: Many women discontinue antidepressants (ADs) when trying to conceive, although risk of depressive relapse is high. We examined the feasibility and potential clinical effect of cognitive behavioral therapy for the prevention of recurrence (CBT-PR) for women with a history of recurrent major depressive disorder (MDD) who planned to discontinue maintenance AD treatment for pregnancy. METHODS: This was an open preliminary study of CBT-PR in women (N = 12) planning or early in pregnancy with remitted MDD on maintenance ADs with a plan to discontinue ADs for pregnancy...
August 2014: Journal of Clinical Psychopharmacology
https://read.qxmd.com/read/25407694/benzodiazepine-use-and-risk-for-alzheimer-disease
#36
EDITORIAL
Carl Salzman, Richard I Shader
No abstract text is available yet for this article.
February 2015: Journal of Clinical Psychopharmacology
https://read.qxmd.com/read/25485636/tardive-dyskinesia-and-tardive-dystonia-with-second-generation-antipsychotics-in-non-elderly-schizophrenic-patients-unexposed-to-first-generation-antipsychotics-a-cross-sectional-and-retrospective-study
#37
JOURNAL ARTICLE
Seunghyong Ryu, Jae Hyun Yoo, Joo Hyun Kim, Ji Sun Choi, Ji Hyun Baek, Kyooseob Ha, Jun Soo Kwon, Kyung Sue Hong
This study investigates the clinical nature, prevalence rates, and associated factors of second-generation antipsychotic (SGA)-related tardive dyskinesia and tardive dystonia. To date, these subjects have not been thoroughly investigated.The subjects were 80 non-elderly schizophrenic patients who received SGAs for more than 1 year without any previous exposure to first-generation antipsychotics. Multiple (≥2) direct assessments of movement symptoms were performed. Hospital records longer than 1 recent year describing any observed tardive movement symptoms were reviewed...
February 2015: Journal of Clinical Psychopharmacology
https://read.qxmd.com/read/25514067/weight-gain-on-antipsychotic-medication-is-associated-with-sustained-use-among-veterans-with-schizophrenia
#38
JOURNAL ARTICLE
Edward P Monnelly, Jennifer Fonda, David R Gagnon, Subha Chittamooru, Elizabeth V Lawler
OBJECTIVE: Continuous antipsychotic treatment is important in schizophrenia, and studies have shown that rates of discontinuation are high. Some studies suggest that weight gain may lead schizophrenic patients to discontinue treatment, whereas other studies show smaller effects of weight gain on medication discontinuation, and some find weight gain associated with symptom improvement. Our retrospective cohort study investigated the effect of weight change on the continued use for 1 year (persistence) of all antipsychotics, then among users of first-generation antipsychotics and second-generation antipsychotics (SGAs), and lastly subgroups of SGAs...
February 2015: Journal of Clinical Psychopharmacology
https://read.qxmd.com/read/25295553/possible-drug-drug-interaction-between-pregabalin-and-clozapine-in-patients-with-schizophrenia-clinical-perspectives
#39
JOURNAL ARTICLE
O Schjerning, S Lykkegaard, P Damkier, J Nielsen
INTRODUCTION: Pregabalin is an antiepileptic drug with anti-anxiety properties and is approved for treatment of generalized anxiety disorder. Anxiety is common in patients with schizophrenia and pregabalin has been suggested as an off-label add-on treatment. METHODS: Pregabalin was added to clozapine in 2 patients with schizophrenia, who both suffered from severe anxiety symptoms. RESULTS: Both patients experienced falls and consequently bone fractures...
January 2015: Pharmacopsychiatry
https://read.qxmd.com/read/25372890/influence-of-concomitant-medications-on-the-total-clearance-and-the-risk-for-supra-therapeutic-plasma-concentrations-of-citalopram-a-population-based-cohort-study
#40
JOURNAL ARTICLE
K Wenzel-Seifert, R Brandl, C Hiemke, E Haen
INTRODUCTION: The main objective of this study was to investigate the influence of the use of multiple medications and other risk factors on citalopram plasma concentrations. METHODS: A retrospective cohort study with a naturalistic population of 957 patients for whom routine therapeutic drug monitoring (TDM) of citalopram had been requested between 2006 and 2013 was conducted. RESULTS: Concomitant drugs inhibiting at least 2 different CYP subtypes involved in the metabolism of citalopram decreased statistically significantly the total clearance (Clt)...
November 2014: Pharmacopsychiatry
label_collection
label_collection
1430
2
3
2014-12-31 12:18:04
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.